Assignee
NANJING LEGEND BIOTECH CO LTD
CN·15 granted patents·38 pending applications·13 citations·filing 2014–2023
Top patents by PatentIndex Score
53 records- 0184US11673954B2Single-domain antibodies and variants thereof against PD-L1NANJING LEGEND BIOTECH CO LTD·Filed 2018·Granted Jun 13, 2023·3 cites·19 claims
- 0283US11447573B2Multispecific antigen binding proteins and methods of use thereofNANJING LEGEND BIOTECH CO LTD·Filed 2017·Granted Sep 20, 2022·3 cites·19 claims
- 0379US11905327B2Single-domain antibodies and variants thereof against TIGITNANJING LEGEND BIOTECH CO LTD·Filed 2018·Granted Feb 20, 2024·1 cites·18 claims
- 0479US11472881B2Single-domain antibodies and variants thereof against CTLA-4NANJING LEGEND BIOTECH CO LTD·Filed 2017·Granted Oct 18, 2022·2 cites·21 claims
- 0575US11958903B2Single-domain antibodies against LAG-3 and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2019·Granted Apr 16, 2024·1 cites·23 claims
- 0674US12168688B2Antibodies and variants thereof against PD-L1NANJING LEGEND BIOTECH CO LTD·Filed 2018·Granted Dec 17, 2024·1 cites·21 claims
- 0774US2024124580A1Single-domain antibodies and variants thereof against tigitNANJING LEGEND BIOTECH CO LTD·Filed 2023·Application pending·0 cites
- 0873US10407508B2Compositions and methods for increasing protein half-life in a serumNANJING LEGEND BIOTECH CO LTD·Filed 2014·Granted Sep 10, 2019·2 cites·30 claims
- 0966US2023059836A1Multispecific antigen binding proteins and methods of use thereofNANJING LEGEND BIOTECH CO LTD·Filed 2022·Application pending·0 cites
- 1063US11932698B2Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2019·Granted Mar 19, 2024·0 cites·24 claims
- 1163US11168146B2Compositions and methods for increasing protein half-life in a serumNANJING LEGEND BIOTECH CO LTD·Filed 2019·Granted Nov 9, 2021·0 cites·20 claims
- 1260US2022241330A1Immune cell receptors comprising cd4 binding moietiesNANJING LEGEND BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 1360US2022265711A1Engineered immune cells comprising a recognition moleculeNANJING LEGEND BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 1459US2025297029A1Anti-gpc3 chimeric antigen receptor and methods of use thereofNANJING LEGEND BIOTECH CO LTD·Filed 2022·Application pending·0 cites
- 1558US2025082754A1Anti-cd33 antibodies and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2022·Application pending·0 cites
- 1657US2025082681A1Antibodies against cll1 and constructs thereofNANJING LEGEND BIOTECH CO LTD·Filed 2022·Application pending·0 cites
- 1757US2024279318A1Antibodies targeting afp peptide/mhc complexes and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2022·Application pending·0 cites
- 1856US2024050474A1Engineered cells and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2022·Application pending·0 cites
- 1956US2023085615A2Engineered t cells and methods of producing thereofNANJING LEGEND BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 2056US2022313738A1Nef-containing t cells and methods of producing thereofNANJING LEGEND BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 2155US2024316201A1Engineered immune effector cells expressing exogenously introduced cytokinesNANJING LEGEND BIOTECH CO LTD·Filed 2022·Application pending·0 cites
- 2254US11401317B2Human-CD123-targeting chimeric receptor ligand and application thereofNANJING LEGEND BIOTECH CO LTD·Filed 2017·Granted Aug 2, 2022·0 cites·23 claims
- 2354US2024010745A1Methods and compositions for depleting natural killer cells and uses thereof in cellular therapiesNANJING LEGEND BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 2454US2023226181A1GENETIC ENGINEERING OF gamma delta T CELLS FOR IMMUNOTHERAPYNANJING LEGEND BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 2554US2024150456A1Engineered immune cells and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2022·Application pending·0 cites
- 2654US2025230430A1Methods for preparing dna libraries and detecting retroviral integration sitesNANJING LEGEND BIOTECH CO LTD·Filed 2023·Application pending·0 cites
- 2754US2024041924A1T cell and antigen-presenting cell engagers and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 2853US2023149461A1Compositions and methods for reducing graft rejection in allogeneic cell therapyNANJING LEGEND BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 2952US2023192883A1Cd19 binding molecules and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 3052US2023338422A1Engineering gamma delta t cells with interleukin-36 for immunotherapyNANJING LEGEND BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 3152US2023250184A1Cd22 binding molecules and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 3252US2024180964A1Chimeric cytokine receptors and uses thereof in cellular therapiesNANJING LEGEND BIOTECH CO LTD·Filed 2022·Application pending·0 cites
- 3351US2021275589A1Co-receptor systems for treating infectious diseasesNANJING LEGEND BIOTECH CO LTD·Filed 2019·Application pending·0 cites
- 3450US11713353B2Single-domain antibodies and variants thereof against PD-1NANJING LEGEND BIOTECH CO LTD·Filed 2019·Granted Aug 1, 2023·0 cites·16 claims
- 3550US2023183296A1Compositions and methods for reducing host rejection of allogeneic cells using simian icp47 and variants thereofNANJING LEGEND BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 3650US2022265709A1Engineered cells and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2019·Application pending·0 cites
- 3749US11505601B2Compositions and methods using a single-domain antibody binding transferrin and protein A for increasing protein half-life in serumNANJING LEGEND BIOTECH CO LTD·Filed 2017·Granted Nov 22, 2022·0 cites·14 claims
- 3849US2023088461A1Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereofNANJING LEGEND BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 3948US2022144960A1Cd30-binding moieties, chimeric antigen receptors, and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2019·Application pending·0 cites
- 4048US2023058669A1Single domain antibodies and chimeric antigen receptors targeting bcma and methods of use thereofNANJING LEGEND BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 4148US2023144237A1Engineered cells and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 4248US2022177524A1Nef-containing t cells and methods of producing thereofNANJING LEGEND BIOTECH CO LTD·Filed 2019·Application pending·0 cites
- 4347US2021070855A1Anti-cd47 antibodies that do not cause significant red blood cell agllutinationNANJING LEGEND BIOTECH CO LTD·Filed 2019·Application pending·0 cites
- 4447US2023192841A1Claudin18.2 binding moieties and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 4547US2022096547A1Modified immune cells expressing flagellin polypeptideNANJING LEGEND BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 4646US2023192805A1Chimeric receptor polypeptides and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 4746US2023257475A1Multispecific chimeric antigen receptors and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 4845US11564945B2Chimeric antigen receptor and use thereofNANJING LEGEND BIOTECH CO LTD·Filed 2017·Granted Jan 31, 2023·0 cites·22 claims
- 4945US2020369770A1Multispecific antigen binding proteins and methods of use thereofNANJING LEGEND BIOTECH CO LTD·Filed 2019·Application pending·0 cites
- 5043US11708410B2Antibodies and variants thereof against TIGITNANJING LEGEND BIOTECH CO LTD·Filed 2019·Granted Jul 25, 2023·0 cites·23 claims
Showing the top 50 of 53 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when NANJING LEGEND BIOTECH CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →